Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11473 posts found.

India: approval for drug treating CKD-associated anaemia

March 7, 2022 Sales and Marketing

Zydus Lifesciences received approval from the Drugs Controller General of India (DCGI) for its new drug application for Oxemia (Desidustat). …
News

Potential breakthrough trial for rare disease Hunter syndrome

February 28, 2022 Sales and Marketing

Actigen has initiated a clinical development programme for GNR-055, a potentially breakthrough treatment for the debilitating, life-limiting, rare disease mucopolysaccharidosis …
News

Phase III data show Dupixent reduced itch in chronic spontaneous urticaria patients

February 28, 2022 Sales and Marketing

Results from a Phase III trial have revealed that adding Dupixent (dupilumab) to standard-of-care antihistamines significanty reduced itch and hives …
News

Urgent need to address mental health crisis among kidney patients

February 28, 2022 Sales and Marketing

Kidney Research UK has released their findings from a survey of 1,000 kidney disease patients in the UK, revealing the …
News

Kapruvia receives positive CHMP opinion for pruritus in hemodialysis patients

February 28, 2022 Sales and Marketing

The CHMP has approved Kapruvia (difelikefalin) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in hemodialysis patients. …
News

CanSinoBIO’s Convidecia approved as heterologous COVID-19 booster in China

February 21, 2022 Sales and Marketing

CanSino Biologics announced that its recombinant novel coronavirus vaccine has been approved by the Joint Prevention and Control Mechanism of …
News

FDA approval of first disease-modifying drug for treatment of rare lifelong anaemia

February 21, 2022 Sales and Marketing

Agios Pharmaceuticals has announced the FDA approval of Pyrukynd (mitapivat), for the treatment of haemolytic anaemia in adults with pyruvate …
News

‘Historic’ results for breast cancer drug and promise for broader use

February 21, 2022 Sales and Marketing

AstraZeneca has shared that its drug, Enhertu, has demonstrated meaningful survival improvements in patients with breast cancer, compared with physician’s …
News

FDA considers approving second COVID-19 booster jab

February 21, 2022 Sales and Marketing

US health regulators are looking at authorising a potential fourth dose of a COVID-19 vaccine, as reported by the Wall …
News

FDA approves Eversense CGM system for use for up to six months

February 14, 2022 Sales and Marketing

The FDA has approved Senseonics’ Eversense E3 CGM System, which includes proprietary sacrificial boronic acid (SBA) technology to extent longevity …
News

AbbVie submits applications for treatment of chronic disease

February 14, 2022 Sales and Marketing

AbbVie has announced the submission of applications seeking the approval of upadacitinib, (RINVOQ®, 15 mg once daily) for the treatment …
News

Gilead’s HIV treatment demonstrates high efficacy and viral suppression at five years

February 14, 2022 Sales and Marketing

Gilead Sciences has announced the presentation of cumulative five-year results from two Phase III studies of Biktarvy. The new, long-term …
News

First UK Lassa fever death in over a decade

February 14, 2022 Sales and Marketing

A patient in Bedfordshire has died from a confirmed case of Lassa fever, the UK Health Security Agency (UKHSA) has …
News
fejiomfxwaeana8

First gene therapy for rare genetic neurodegenerative disorder in children

February 7, 2022 Sales and Marketing

NICE has published a draft highly specialised technologies guidance, recommending gene therapy atidarsagene autotemcel for some children with the rare, …
News

NICE approves new treatment for chronic heart failure

February 7, 2022 Sales and Marketing

Empagliflozin (Jardiance®) has received a positive NICE recommendation for the treatment of chronic heart failure. NICE has announced that empagliflozin …
News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024